Computational tools in the discovery of new G-quadruplex ligands with potential anticancer activity

Current Topics in Medicinal Chemistry

Volumn 12, Issue 24, 2012, Pages 2843-2856

  Castillo González, Daimel ^a,b,c   Pérez Machado, Gisselle ^a,d   Pallardó, Federico ^d   Garrigues Pelufo, Teresa María ^d   Cabrera Pérez, Miguel Angel ^a,d  

^a CENTRAL UNIVERSITY OF LAS VILLAS   (Cuba)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM U869   (France)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Cancer; Drug design; G quadruplex; Oncogenes

Indexed keywords

GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GUANINE QUADRUPLEX; GUANOSINE PHOSPHATE; IMIDAZOLE DERIVATIVE; MYC PROTEIN; TELOMERASE; TELOMERIC REPEAT BINDING FACTOR 1; TRIAZINE DERIVATIVE; WERNER SYNDROME PROTEIN; ANTINEOPLASTIC AGENT; GUANINE; LIGAND; TERT PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; COMPUTER AIDED DESIGN; DOWN REGULATION; DRUG SCREENING; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HYDROGEN BOND; IC50; MOLECULAR DOCKING; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEIVER OPERATING CHARACTERISTIC; STRUCTURE ACTIVITY RELATION; TELOMERE HOMEOSTASIS; X RAY CRYSTALLOGRAPHY; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECT; GENETICS; METABOLISM; NEOPLASM; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; TELOMERE;

ANTINEOPLASTIC AGENTS; COMPUTER-AIDED DESIGN; DRUG DESIGN; DRUG DISCOVERY; G-QUADRUPLEXES; GUANINE; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; NEOPLASMS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TELOMERASE; TELOMERE;

EID: 84883720848     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611212240010     Document Type: Article

References (230)

1. Trichopoulos, D.; Lagiou, P.; Adami, H.O. Towards an integratedmodel for breast cancer etiology: the crucial role of the number ofmammary tissue-specific stem cells. Breast Cancer Res.., 2005, 7,13-17.
2. Cairney, C.J.; Bilsland, A.E.; Evans, T.R.; Roffey, J.; Bennett, D.C.; Narita, M.; Torrance, C.J.; Keith, W.N. Cancer cellsenescence: a new frontier in drug development. Drug Discov.Today, 2012, 17, 269-276.
3. Dalla Via, L.; Nardon, C.; Fregona, D. Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: achallenge for the future. Future Med. Chem., 2012, 4, 525-543.
4. Muller-Schiffmann, A.; Sticht, H.; Korth, C. Hybrid compounds:from simple combinations to nanomachines. BioDrugs, 2012, 26,21-31.
5. Balasubramanian, S.; Hurley, L.; Neidle, S. Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? Nat.Rev. Drug Discov., 2011, 10, 261-275.
6. Sen, D.; Gilbert, W. Formation of parallel four-stranded complexesby guanine-rich motif for meiosis. Nature, 1998, 334, 364-366.
7. Sundquist, W.I.; Klug, A. Telomeric DNA dimerizes by formationof guanine tetrads between hairpin loops.. Nature, 1989, 342, 825-829.
8. Membrino, A.; Cogoi, S.; Pedersen, E.B.; Xodo, L.E. G4-DNAFormation in the HRAS Promoter and Rational Design of DecoyOligonucleotides for Cancer Therapy. PLoS One, 2011, 6, e24421.
9. Miller, K.M.; Rodriguez, R. G-quadruplexes: selective DNAtargeting for cancer therapeutics? Expert Rev. Clin. Pharmacol.,2011, 4, 139-142.
10. Amato, J.; Pagano, B.; Borbone, N.; Oliviero, G.; Gabelica, V.; Pauw, E.D.; D'Errico, S.; Piccialli, V.; Varra, M.; Giancola, C.; Piccialli, G.; Mayol, L. Targeting G-quadruplex structure in thehuman c-Kit promoter with short PNA sequences. Bioconjug.Chem., 2011, 22, 654-663.
11. Parkinson, G.N. Fundamentals of Quadruplex Structures. In Quadruplex Nucleic Acids, Neidle, S.; Balasubramanian, S., Eds.Royal Society of Chemistry: Cambridge, 2006; p1-p27.
12. Phan, A.; Kuryavyi, V.; Ngoc, K.; Patel, D. Structural Diversity ofG-Quadruplex Scaffolds. In Quadruplex Nucleic Acid Neidle, S.; Balasubramanian, S., Eds. Royal Society of Chemistry: Cambridge,2006; pp 81-99.
13. Han, H.; Hurley, L.H. G-quadruplex DNA: a potential target foranti-cancer drug design. Trends Pharmacol. Sci., 2000, 21, 136-142.
14. Ma, D.; Pui-Yan Ma, V.; Shiu-Hin Chan, D.; Leung, K.; Zhong, H.; Leung, C. In silico screening of quadruplex-binding ligands. Methods, 2012, 57, 106-114.
15. Mergny, J.L.; Gros, J.; De Cian, A.; Bourdoncle, A.; Rosu, F.; Saccà, B.; Guittat, L.; Amrane, S.; Mills, M.; Alberti, P.; Lacroix, L. Energetics, Kinetics and Dynamics of QuadruplexFolding. In Quadruplex Nucleic Acids Neidle, S.;Balasubramanian, S., Eds. Royal Society of Chemistry: Cambridge,2006; pp 31-72.
16. Trotta, R.; De Tito, S.; Lauri, I.; La Pietra, V.; Marinelli, L.; Cosconati, S.; Martino, L.; Conte, M.; Mayol, L.; Novellino, E.; Randazzo, A. A more detailed picture of the interactions betweenvirtual screening-derived hits and the DNA G-quadruplex: NMR,molecular modelling and ITC studies. Biochimie, 2011, 93 1280-1287.
17. Hurley, L.H.; Wheelhouse, R.T.; Sun, D.; Kerwin, S.M.; Salazar, M.; Fedoroff, O.Y.; Han, F.X.; Han, H.; Izbicka, E.; Von Hoff, D.D. G-quadruplexes as targets for drug design. Pharmacol. Ther.,2000, 85, 141-158.
18. Monchaud, D.; Teulade-Fichou, M.P. A hitchhiker's guide to G-quadruplex ligands. Org. Biomol. Chem., 2008, 6, 627-636.
19. Balasubramanian, S.; Neidle, S. G-quadruplex nucleic acids astherapeutic targets. Curr. Opin. Chem. Biol., 2009, 13, 345-353.
20. Neidle, S. Genomic Quadruplexes as Therapeutic Targets. InTherapeutic Applications of Quadruplex Nucleic Acids., AcademicPress: Boston, 2012; pp 119-139.
21. Nagatoishi, S.; Isono, N.; Tsumoto, K.; Sugimoto, N. Loopresidues of thrombin-binding DNA aptamer impact G-quadruplexstability and thrombin binding. Biochimie, 2011, 93, 1231-1238.
22. Dexheimer, T.; Fry, M.; Hurley, L. DNA Quadruplexes and GeneRegulation. In Quadruplex Nucleic Acids, Neidle, S.;Balasubramanian, S., Eds. Royal Society of Chemistry Cambridge,2006; pp 180-207.
23. Neidle, S. Introduction: Quadruplexes and their Biology InTherapeutic Applications of Quadruplex Nucleic Acids, AcademicPress: Boston 2012; pp 1-20.
24. Henderson, E.; Hardin, C.C.; Walk, S.K.; Jr. Blackburn, E.H. Telomeric DNA oligonucleotides form novel intramolecularstructures containing guanine-guanine base pairs.. Biochemistry,1987, 51, 899-908.
25. Neidle, S. Introduction: Quadruplexes and their Biology. InTherapeutic Applications of Quadruplex Nucleic Acids, AcademicPress: Boston 2012; pp 1-20.
26. Todd, A.K.; Johnston, M.; Neidle, S. Highly prevalent putativequadruplex sequence motifs in human DNA. Nucleic Acids Res. , 2005, 33, 2901-2907.
27. Huppert, J.L.; Balasubramanian, S. Prevalence of quadruplexes inthe human genome. Nucleic Acids Res.., 2005, 33(9), 2908-2916.
28. D’Antonio, L.; Bagga, P. Computational methods for predictingintramolecular G-quadruplexes in nucleotide sequencesProceedings of the 2004 IEEE Computational SystemsBioinformatics Conference (CSB 2004), 2004.
29. Parkinson, G.N. Fundamentals of Quadruplex Structures. InQuadruplex Nucleic Acids, Neidle, S.; Balasubramanian, S., Eds.Royal Society of Chemistry: Cambridge, 2006; pp 1-27.
30. Neidle, S.; Parkinson, G.N. Quadruplex DNA crystal structures anddrug design. Biochimie, 2008, 90, 1184-1196.
31. Hud, N.; Plavec, J. The Role of Cations in Determining QuadruplexStructure and Stability. In Quadruplex Nucleic Acid Neidle, S.; Balasubramanian, S., Eds. Royal Society of Chemistry: Cambridge,2006; pp 100-130.
32. Jing, N.; Sha, W.; Li, Y.; Xiong, W.; Tweardy, D. Rational drugdesign of G quartet DNA as anticancer agents. Curr. Pharm. Des.,2005, 11, 2841-2854.
33. Maizels, N. Quadruplexes and the Biology of G-Rich GenomicRegions. In Quadruplex Nucleic Acids, Neidle, S.; Balasubramanian, S., Eds. Royal Society of Chemistry: Cambridge,2006; pp 228-252.
34. Zahler, A.M.; Williamson, J.R.; Cech, T.R.; Prescott, D.M. Inhibition of telomerase by G-quartet DNA structures. Nature,1991, 350, 718-720.
35. Kaushik, M.; Kaushik, S.; Bansal, A.; Saxena, S.; Kukreti, S. Structural diversity and specific recognition of four stranded G-quadruplex DNA. Curr. Mol. Med., 2011, 11, 744-769.
36. Cummaro, A.; Fotticchia, I.; Franceschin, M.; Giancola, C.; Petraccone, L. Binding properties of human telomeric quadruplexmultimers: a new route for drug design. Biochimie, 2011, 93, 1392-1400.
37. Patel, D.J.; Phan, A.T.; Kuryavyi, V. Human telomere, oncogenicpromoter and 5'-UTR G-quadruplexes: diverse higher order DNAand RNA targets for cancer therapeutics. Nucleic Acids Res., 2007,35, 7429-55.
38. Phan, A.T. Human telomeric G-quadruplex: structures of DNA andRNA sequences. FEBS J, 2010, 277, 1107-1117.
39. Moyzis, R.K.; Buckingham, J.M.; Cram, I.S.; Dani, M.; Deaven, L.L.; Jones, M.D. A highly conserved repetitive DNA sequence(TTAGGG)n present at the telomeres of human chromosomes.Proc. Natl. Acad. Sci. USA, 1988, 85, 6622-6626.
40. Meyne, J.; Ratliff, R.L.; Moyzis, R.K. Conservation of the humantelomere sequence (TTAGGG)n among vertebrates. Proc. Natl.Acad. Sci. USA, 1989, 86, 7049-7053.
41. Neidle, S.; Parkinson, G. Telomere maintenance as a target foranticancer drug discovery. Nat. Rev. Drug Discov., 2002, 1, 383-393.
42. Sampedro Camarena, F.; Cano Serral, G.; Sampedro Santalo, F. Telomerase and telomere dynamics in ageing and cancer: currentstatus and future directions. Clin. Transl. Oncol., 2007, 9, 145-154.
43. Riou, J.F.; Morjani, H.; Trentesaux, C. [Telomeres and telomerase, new targets for anticancer chemotherapy]. Ann. Pharm. Fr., 2006,64, 97-105.
44. Olaussen, K.A.; Dubrana, K.; Domont, J.; Spano, J.P.; Sabatier, L.; Soria, J.C. Telomeres and telomerase as targets for anticancer drugdevelopment. Crit. Rev. Oncol. Hematol., 2006, 57, 191-214.
45. Folini, M.; Venturini, L.; Cimino-Reale, G.; Zaffaroni, N. Telomeres as targets for anticancer therapies. Expert Opin. Ther.Targets, 2011, 15, 579-593.
46. Wu, X.M.; Tang, W.R.; Luo, Y. [ALT--alternative lengthening oftelomere]. Yi Chuan, 2009, 31, 1185-1191.
47. Terrin, L.; Rampazzo, E.; Pucciarelli, S.; Agostini, M.; Bertorelle, R.; Esposito, G.; DelBianco, P.; Nitti, D.; De Rossi, A. Relationship between tumor and plasma levels of hTERT mRNA inpatients with colorectal cancer: implications for monitoring ofneoplastic disease. Clin. Cancer Res.., 2008, 14, 7444-7451.
48. Huang, F.C.; Chang, C.C.; Wang, J.M.; Chang, T.C.; Lin, J.J. Induction of senescence in cancer cells by a G-quadruplexstabilizer BMVC4 is independent of its telomerase inhibitoryactivity. Br. J. Pharmacol., 2012
49. Neidle, S. The Biology and Pharmacology of TelomericQuadruplex Ligands. In Therapeutic Applications of QuadruplexNucleic Acids, Academic Press: Boston, 2012; pp 109-117.
50. Bhattacharya, S.; Chaudhuri, P.; Jain, A.; Paul, A. SymmetricalBisbenzimidazoles with Benzenediyl Spacer: The Role of theShape of the Ligand on the Stabilization and Structural Alterationsin Telomeric G-Quadruplex DNA and Telomerase Inhibition. Bioconjugate Chem., 2010, 21, 1148-1159
51. Riou, J.; Gomez, D.; Morjani, H.; Trentesaux, C. QuadruplexLigand Recognition: Biological Aspects. In Quadruplex NucleicAcids Neidle, S.; Balasubramanian, S., Eds. Royal Society ofChemistry Cambridge 2006; pp 154-175
52. Davis, J.T. G-quartets 40 years later: from 5'-GMP to molecularbiology and supramolecular chemistry. Angew. Chem. Int. Ed.Engl., 2004, 43, 668-698.
53. Zhang, R.; Lin, Y.; Zhang, C.T. Greglist: a database listingpotential G-quadruplex regulated genes. Nucleic Acids Res., 2008,36, 372-376.
54. Huppert, J.L. Quadruplexes in the Genome In Quadruplex NucleicAcids, Neidle, S.; Balasubramanian, S., Eds. Royar Society ofChemistry Cambridge, 2006; pp 208-223.
55. Rahman, K.M.; Tizkova, K.; Reszka, A.P.; Neidle, S.; Thurston, D.E. Identification of novel telomeric G-quadruplex-targetingchemical scaffolds through screening of three NCI libraries. Bioorg. Med. Chem., 2012, 22, 3006-3010.
56. Fry, M.; Leob, L.A. The fragile X syndrome d(CGG)n nucleotiderepeats form a stable tetrahelical structure. Proc. Natl. Acad. Sci.USA, 1994, 91, 4950-4954.
57. Sundquist, W.I.; Heaphy, S. Evidence for interstrand quadruplexformation in the dimerization of human immunodeficiency virus 1genomic RNA. Proc. Natl. Acad. Sci. USA, 1993, 90, 3393-3397.
58. Awang, G.; Sen, D. Mode of dimerization of HIV-1 genomic RNA.Biochemistry, 1993, 32, 11453-11457.
59. Lemarteleur, T.; Gomez, D.; Paterski, R.; Mandine, E.; Mailliet, P.; Riou, J.F. Stabilization of the c-myc gene promoter quadruplex byspecific ligands' inhibitors of telomerase. Biochem. Biophys. Res.Commun., 2004, 323, 802-808.
60. Brooks, T.; Kendrick, S.; Hurley, L. Making sense of G-quadruplexand i-motif functions in oncogene promoters. FEBS Journal, 2010,277, 3459-3469.
61. Menendez, C.; Frees, S.; Bagga, P.S. QGRS-H Predictor: a webserver for predicting homologous quadruplex forming G-richsequence motifs in nucleotide sequences. Nucleic Acids Res., 2012
62. Yang, D.; Okamoto, K. Structural insights into G-quadruplexes:towards new anticancer drugs. Future Med. Chem., 2010, 2, 619-646.
63. Flores, I.; Evan, G.; Blasco, M.A. Genetic analysis of myc andtelomerase interactions in vivo. Mol. Cell Biol., 2006, 26, 6130-6138.
64. Mergny, J.L.; Riou, J.F.; Mailliet, P.; Teulade-Fichou, M.P.; Gilson, E. Natural and pharmacological regulation of telomerase. Nucleic Acids Res., 2002, 30, 839-865.
65. Siddiqui-Jain, A.; Grand, C.L.; Bearss, D.J.; Hurley, L.H. Directevidence for a G-quadruplex in a promoter region and its targetingwith a small molecule to repress c-MYC transcription. Proc. Natl.Acad. Sci. USA, 2002, 99, 11593-11598.
66. Brown, R.V.; Danford, F.L.; Gokhale, V.; Hurley, L.H.; Brooks, T. A. Demonstration that drug-targeted down-regulation of MYC innon-Hodgkins lymphoma is directly mediated through the promoterG-quadruplex. J. Biol. Chem., 2011, 286, 41018-41027.
67. Biroccio, A.; Amodei, S.; Antonelli, A.; Benassi, B.; Zupi, G. Inhibition of c-Myc oncoprotein limits the growth of humanmelanoma cells by inducing cellular crisis. J. Biol. Chem., 2003,278, 35693-35701.
68. Peng, D.; Tan, J.-H.; Chen, S.-B.; Ou, T.-M.; Gu, L.-Q.; Huang, Z.-S. Bisaryldiketene derivatives: new class of selective ligands for c-myc G-quadruplex DNA. Bioorg. Med. Chem., 2010, 18, 8235-8242.
69. Hurley, L.H.; Von Hoff, D.D.; Siddiqui-Jain, A.; Yang, D. Drugtargeting of the c-MYC promoter to repress gene expression via aG-quadruplex silencer element. Semin. Oncol., 2006, 33, 498-512.
70. Grandori, C.; Robinson, K.L.; Galloway, D.A.; Swisshelm, K.Functional link between Myc and the Werner gene intumorigenesis. Cell Cycle, 2004, 3, 22-25.
71. Grandori, C.; Wu, K.J.; Fernandez, P.; Ngouenet, C.; Grim, J.; Clurman, B.E.; Moser, M.J.; Oshima, J.; Russell, D.W.; Swisshelm, K.; Frank, S.; Amati, B.; Dalla-Favera, R.; Monnat, R.J., Jr. Wernersyndrome protein limits MYC-induced cellular senescence. GenesDev., 2003, 17, 1569-1574.
72. Li, J.L.; Harrison, R.J.; Reszka, A.P.; Brosh, R.M., Jr.; Bohr, V.A.; Neidle, S.; Hickson, I.D. Inhibition of the Bloom's and Werner'ssyndrome helicases by G-quadruplex interacting ligands.Biochemistry, 2001, 40, 15194-15202.
73. Han, H.; Bennett, R.J.; Hurley, L.H. Inhibition of unwinding of G-quadruplex structures by Sgs1 helicase in the presence of N,N'-bis [2-(1-piperidino)ethyl]-3,4,9,10-perylenetetracarboxylicdiimide, a G-quadruplex-interactive ligand. Biochemistry, 2000, 39,9311-9316.
74. Rankin, S.; Reszka, A.P.; Huppert, J.; Zloh, M.; Parkinson, G.N.; Todd, A.K.; Ladame, S.; Balasubramanian, S.; Neidle, S. PutativeDNA quadruplex formation within the human c-kit oncogene. J.Am. Chem. Soc., 2005, 127, 10584-10589.
75. Fernando, H.; Reszka, A.P.; Huppert, J.; Ladame, S.; Rankin, S.; Venkitaraman, A.R.; Neidle, S.; Balasubramanian, S. A conservedquadruplex motif located in a transcription activation site of thehuman c-kit oncogene. Biochemistry, 2006, 45, 7854-7860.
76. Todd, A.K.; Haider, S.M.; Parkinson, G.N.; Neidle, S. Sequenceoccurrence and structural uniqueness of a G-quadruplex in thehuman c-kit promoter. Nucleic Acids Res., 2007, 35, 5799-5808.
77. Fletcher, J.A.; Rubin, B.P. KIT mutations in GIST. Curr. Opin.Genet. Dev., 2007, 7, 3-7.
78. Gunaratnam, M.; Swank, S.; Haider, S.M.; Galesa, K.; Reszka, A.P.; Beltran, M.; Cuenca, F.; Fletcher, J.A.; Neidle, S. Targetinghuman gastrointestinal stromal tumor cells with a quadruplex-binding small molecule. J. Med. Chem., 2009, 52, 3774-3783.
79. McLuckie, K.I.; Waller, Z.A.; Sanders, D.A.; Alves, D.; Rodriguez, R.; Dash, J.; McKenzie, G.J.; Venkitaraman, A.R.; Balasubramanian, S. G-quadruplex-binding benzo [a]phenoxazinesdown-regulate c-KIT expression in human gastric carcinoma cells.J. Am. Chem. Soc., 2011, 133, 2658-2663.
80. Balasubramanian, S.; Hurley, L.H.; Neidle, S. Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? Nat.Rev. Drug Discov., 2011, 10, 261-275.
81. Neidle, S. 9 - Design Principles for Quadruplex-binding SmallMolecules. In Therapeutic Applications of Quadruplex NucleicAcids, Academic Press: Boston, 2012; pp 151-174.
82. Gavathiotis, E.; Heald, R.A.; Stevens, M.F.; Searle, M.S. Drugrecognition and stabilisation of the parallel-stranded DNAquadruplex d(TTAGGGT)4 containing the human telomeric repeat J. Mol. Biol., 2003, 334, 25-36.
83. Haider, S.M.; Parkinson, G.N.; Neidle, S. Structure of a G-quadruplex-ligand complex. J. Mol. Biol., 2003, 326, 117-125.
84. Campbell, N.H.; Parkinson, G.N.; Reszka, A.P.; Neidle, S. Structural basis of DNA quadruplex recognition by an acridinedrug. J. Am. Chem. Soc., 2008, 130, 6722-6724.
85. Parkinson, G.N.; Cuenca, F.; Neidle, S. Topology conservation andloop flexibility in quadruplex-drug recognition: crystal structures ofinter- and intramolecular telomeric DNA quadruplex-drugcomplexes. J. Mol. Biol., 2008, 381, 1145-1156.
86. Phan, A.T.; Kuryavyi, V.; Gaw, H.Y.; Patel, D.J. Small-moleculeinteraction with a five-guanine-tract G-quadruplex structure fromthe human MYC promoter. Nat. Chem. Biol., 2005, 1, 167-173.
87. Parkinson Gn Fau-Ghosh, R.; Ghosh R Fau-Neidle, S.; Neidle, S. Structural basis for binding of porphyrin to human telomeres. Biochemistry, 2007, 46, 2390-7.
88. Collie, G.W.; Sparapani, S.; Parkinson, G.N.; Neidle, S. Structuralbasis of telomeric RNA quadruplex--acridine ligand recognition. J.Am. Chem. Soc., 2011, 133, 2721-2728.
89. Holt, P.A.; Buscaglia, R.; Trent, J.O.; Chaires, J.B. A DiscoveryFunnel for Nucleic Acid Binding Drug Candidates. Drug Dev. Res.,2011, 72, 178-186.
90. Zoete, V.; Grosdidier, A.; Michielin, O. Docking, virtual highthroughput screening and in silico fragment-based drug design. J.Cell Mol. Med., 2009, 13, 238-248.
91. Rester, U. From virtuality to reality - Virtual screening in leaddiscovery and lead optimization: a medicinal chemistryperspective. Curr. Opin. Drug Discov. Devel., 2008, 11, 559-568.
92. Sternberg, M.J.E.; Muggleton, S.H. Structure ActivityRelationships (SAR) and Pharmacophore Discovery UsingInductive Logic Programming (ILP). QSAR Comb. Sci., 2003, 22,1-6.
93. Concu, R.; Podda, G.; Ubeira, F.M.; Gonzalez-Diaz, H. Review ofQSAR models for enzyme classes of drug targets: Theoreticalbackground and applications in parasites, hosts, and otherorganisms. Curr. Pharm. Des., 2010, 16, 2710-2723.
94. Darnag, R.; Mostapha Mazouz, E.L.; Schmitzer, A.; Villemin, D.; Jarid, A.; Cherqaoui, D. Support vector machines: development ofQSAR models for predicting anti-HIV-1 activity of TIBOderivatives. Eur. J. Med. Chem., 2010, 45, 1590-1597.
95. Hristozov, D.; Gasteiger, J.; Da Costa, F.B. Multilabeledclassification approach to find a plant source for terpenoids. J.Chem. Inf. Model., 2008, 48, 56-67.
96. Liu, H.; Papa, E.; Walker, J.D.; Gramatica, P. In silico screening ofestrogen-like chemicals based on different nonlinear classificationmodels. J. Mol. Graph. Model., 2007, 26, 135-144.
97. Vega, M.C.; Rolon, M.; Montero-Torres, A.; Fonseca-Berzal, C.; Escario, J.A.; Gomez-Barrio, A.; Galvez, J.; Marrero-Ponce, Y.; Aran, V.J. Synthesis, biological evaluation and chemometricanalysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug. Eur. J.Med. Chem., 2012, 58C, 214-227.
98. Castillo-Garit, J.A.; Del Toro-Cortes, O.; Kouznetsov, V.V.; Puentes, C.O.; Romero Bohorquez, A.R.; Vega, M.C.; Rolon, M.; Escario, J.A.; Gomez-Barrio, A.; Marrero-Ponce, Y.; Torrens, F.; Abad, C. Identification in silico and in vitro of noveltrypanosomicidal drug-like compounds. Chem. Biol. Drug Des.,2012, 80, 38-45.
99. Castillo-Garit, J.A.; Marrero-Ponce, Y.; Torrens, F.; Rotondo, R. Atom-based stochastic and non-stochastic 3D-chiral bilinearindices and their applications to central chirality codification. J.Mol. Graph. Model., 2007, 26, 32-47.
100. Le-Thi-Thu, H.; Casanola-Martin, G.M.; Marrero-Ponce, Y.; Rescigno, A.; Saso, L.; Parmar, V.S.; Torrens, F.; Abad, C. Novelcoumarin-based tyrosinase inhibitors discovered by OECDprinciples-validated QSAR approach from an enlarged, balanceddatabase. Mol. Divers., 2011, 15, 507-520.
101. Casañola-Martin, G.M.; Marrero-Ponce, Y.; Khan, M.T.; Khan, S.B.; Torrens, F.; Perez-Jimenez, F.; Rescigno, A.; Abad, C. Bond-based 2D quadratic fingerprints in QSAR studies: virtual and invitro tyrosinase inhibitory activity elucidation. Chem. Biol. DrugDes., 2010, 76, 538-545.
102. Castillo-Garit, J.A.; Marrero-Ponce, Y.; Torrens, F.; Garcia-Domenech, R.; Romero-Zaldivar, V. Bond-based 3D-chiral linearindices: theory and QSAR applications to central chiralitycodification. J. Comput. Chem., 2008, 29, 2500-2512.
103. Speck-Planche, A.; Luan, F.; Cordeiro, M.N. Role of ligand-baseddrug design methodologies toward the discovery of new anti-Alzheimer agents: futures perspectives in Fragment-Based LigandDesign. Curr. Med. Chem., 2012, 19, 1635-1645.
104. Speck-Planche, A.; Luan, F.; Cordeiro, M.N. Discovery of anti-Alzheimer agents: current ligand-based approaches toward thedesign of acetylcholinesterase inhibitors. Mini Rev. Med. Chem.,2012, 12, 583-591.
105. Speck-Planche, A.; Kleandrova, V.V.; Scotti, M.T. Fragment-basedapproach for the in silico discovery of multi-target insecticides.Chemometr. Intell. Lab. Syst., 2012, 111, 39-45.
106. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Chemoinformatics in multi-target drug discovery for anti-cancertherapy: in silico design of potent and versatile anti-brain tumoragents. Anticancer Agents Med. Chem., 2012, 12, 678-685.
107. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Insilico discovery and virtual screening of multi-target inhibitors forproteins in Mycobacterium tuberculosis. Comb. Chem. HighThroughput Screen., 2012, 15, 666-673.
108. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Predicting multiple ecotoxicological profiles in agrochemicalfungicides: a multi-species chemoinformatic approach. Ecotoxicol.Environ. Saf., 2012, 80, 308-313.
109. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Chemoinformatics in anti-cancer chemotherapy: multi-targetQSAR model for the in silico discovery of anti-breast canceragents. Eur. J. Pharm. Sci., 2012, 47, 273-279.
110. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Aligand-based approach for the in silico discovery of multi-targetinhibitors for proteins associated with HIV infection. Mol. Biosyst.,2012, 8, 2188-2196.
111. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Rational drug design for anti-cancer chemotherapy: multi-targetQSAR models for the in silico discovery of anti-colorectal canceragents. Bioorg. Med. Chem., 2012, 20, 4848-4855.
112. Speck-Planche, A.; Kleandrova, V.V. QSAR and moleculardocking techniques for the discovery of potent monoamine oxidaseB inhibitors: Computer-aided generation of new rasagilinebioisosteres. Curr. Top. Med. Chem., 2012, 12, 1734-1747.
113. Speck-Planche, A.; Kleandrova, V.V. In silico design of multi-target inhibitors for C-C chemokine receptors using substructuraldescriptors. Mol. Divers., 2012, 16, 183-191.
114. Speck-Planche, A.; Cordeiro, M.N. Computer-aided drug designmethodologies toward the design of anti-hepatitis C agents. Curr.Top. Med. Chem., 2012, 12, 802-813.
115. Molina, E.; Sobarzo-Sanchez, E.; Speck-Planche, A.; Matos, M.J.; Uriarte, E.; Santana, L.; Yanez, M.; Orallo, F. Monoamino oxidasea: an interesting pharmacological target for the development ofmulti-target QSAR. Mini Rev. Med. Chem., 2012, 12, 947-958.
116. Speck-Planche, A.; Kleandrova, V.V.; Rojas-Vargas, J.A. QSARmodel toward the rational design of new agrochemical fungicideswith a defined resistance risk using substructural descriptors. Mol.Divers., 2011, 15, 901-909.
117. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Multi-target drug discovery in anti-cancer therapy: fragment-basedapproach toward the design of potent and versatile anti-prostatecancer agents. Bioorg. Med. Chem., 2011, 19, 6239-6244.
118. Speck-Planche, A.; Guilarte-Montero, L.; Yera-Bueno, R.; Rojas-Vargas, J.A.; Garcia-Lopez, A.; Uriarte, E.; Molina-Perez, E.Rational design of new agrochemical fungicides using substructuraldescriptors. Pest Manag. Sci., 2011, 67, 438-445.
119. Speck-Planche, A.; Cordeiro, M.N.D.S. Application ofBioinformatics for the search of novel anti-viral therapies: Rationaldesign of anti-herpes agents. Curr. Bioinform., 2011, 6, 81-93.
120. Speck-Planche, A.; Cordeiro, M.N.; Guilarte-Montero, L.; Yera-Bueno, R. Current computational approaches towards the rationaldesign of new insecticidal agents. Curr. Comput. Aided Drug Des.,2011, 7, 304-314.
121. Speck-Planche, A.; Cordeiro, M.N. Current drug design of anti-HIV agents through the inhibition of C-C chemokine receptor type5. Curr. Comput. Aided Drug Des., 2011, 7, 238-248.
122. Speck-Planche, A.; Scotti, M.T.; de Paulo-Emerenciano, V. Currentpharmaceutical design of antituberculosis drugs: futureperspectives. Curr. Pharm. Des., 2010, 16, 2656-2665.
123. Tenorio-Borroto, E.; Penuelas Rivas, C.G.; Vasquez Chagoyan, J.C.; Castanedo, N.; Prado-Prado, F.J.; Garcia-Mera, X.; Gonzalez-Diaz, H. ANN multiplexing model of drugs effect on macrophages;theoretical and flow cytometry study on the cytotoxicity of the anti-microbial drug G1 in spleen. Bioorg. Med. Chem., 2012, 20, 6181-6194.
124. Riera-Fernandez, P.; Martin-Romalde, R.; Prado-Prado, F.J.; Escobar, M.; Munteanu, C.R.; Concu, R.; Duardo-Sanchez, A.; Gonzalez-Diaz, H. From QSAR models of drugs to complexnetworks: state-of-art review and introduction of new Markov-spectral moments indices. Curr. Top. Med. Chem., 2012, 12, 927-960.
125. Gonzalez-Diaz, H.; Riera-Fernandez, P. New Markov-Autocorrelation Indices for Re-evaluation of Links in Chemical andBiological Complex Networks used in Metabolomics, Parasitology,Neurosciences, and Epidemiology. J. Chem. Inf. Model., 2012, 52,331-40.
126. Gonzalez-Diaz, H.; Munteanu, C.R.; Postelnicu, L.; Prado-Prado, F.; Gestal, M.; Pazos, A. LIBP-Pred: web server for lipid bindingproteins using structural network parameters; PDB mining ofhuman cancer biomarkers and drug targets in parasites and bacteria. Mol. Biosyst., 2012, 8, 851-862.
127. Aguiar-Pulido, V.; Munteanu, C.R.; Seoane, J.A.; Fernandez-Blanco, E.; Perez-Montoto, L.G.; Gonzalez-Diaz, H.; Dorado, J. Naive Bayes QSDR classification based on spiral-graph Shannonentropies for protein biomarkers in human colon cancer. Mol.Biosyst., 2012, 8, 1716-1722.
128. Prado-Prado, F.; Garcia-Mera, X.; Abeijon, P.; Alonso, N.; Caamano, O.; Yanez, M.; Garate, T.; Mezo, M.; Gonzalez-Warleta, M.; Muino, L.; Ubeira, F.M.; Gonzalez-Diaz, H. Using entropy ofdrug and protein graphs to predict FDA drug-target network:theoretic-experimental study of MAO inhibitors and hemoglobinpeptides from Fasciola hepatica. Eur. J. Med. Chem., 2011, 46,1074-1094.
129. Rodriguez-Soca, Y.; Munteanu, C.R.; Dorado, J.; Pazos, A.; Prado-Prado, F.J.; Gonzalez-Diaz, H. Trypano-PPI: a web server forprediction of unique targets in trypanosome proteome by usingelectrostatic parameters of protein-protein interactions. J. ProteomeRes., 2010, 9, 1182-1190.
130. Prado-Prado, F.J.; Garcia-Mera, X.; Gonzalez-Diaz, H. Multi-targetspectral moment QSAR versus ANN for antiparasitic drugs againstdifferent parasite species. Bioorg. Med. Chem., 2010, 18, 2225-2231.
131. Gonzalez-Diaz, H.; Dea-Ayuela, M.A.; Perez-Montoto, L.G.; Prado-Prado, F.J.; Aguero-Chapin, G.; Bolas-Fernandez, F.; Vazquez-Padron, R.I.; Ubeira, F.M. QSAR for RNases andtheoretic-experimental study of molecular diversity on peptidemass fingerprints of a new Leishmania infantum protein. Mol.Divers., 2010, 14, 349-369.
132. Gonzalez-Diaz, H. Network topological indices, drug metabolism,and distribution. Curr. Drug Metab., 2010, 11, 283-284.
133. Vina, D.; Uriarte, E.; Orallo, F.; Gonzalez-Diaz, H. Alignment-freeprediction of a drug-target complex network based on parametersof drug connectivity and protein sequence of receptors. Mol.Pharm., 2009, 6, 825-835.
134. Vilar, S.; Gonzalez-Diaz, H.; Santana, L.; Uriarte, E. A network-QSAR model for prediction of genetic-component biomarkers inhuman colorectal cancer. J. Theor. Biol., 2009, 261, 449-458.
135. Prado-Prado, F.J.; Uriarte, E.; Borges, F.; Gonzalez-Diaz, H. Multi-target spectral moments for QSAR and Complex Networks study ofantibacterial drugs. J. Med. Chem.Eur. J. Med. Chem., 2009, 44,4516-4521.
136. Munteanu, C.R.; Vazquez, J.M.; Dorado, J.; Sierra, A.P.; Sanchez-Gonzalez, A.; Prado-Prado, F.J.; Gonzalez-Diaz, H. Complexnetwork spectral moments for ATCUN motif DNA cleavage: firstpredictive study on proteins of human pathogen parasites. J.Proteome Res., 2009, 8, 5219-5228.
137. Munteanu, C.R.; Magalhaes, A.L.; Uriarte, E.; Gonzalez-Diaz, H. Multi-target QPDR classification model for human breast andcolon cancer-related proteins using star graph topological indices.J. Theor. Biol., 2009, 257, 303-311.
138. Todechini, R.; Consonni, V. Handbook of Molecular Descriptors, Mannhold, R., Kubinyi, H., Timmerman, H., Eds ed.; Wiley-ECH,2000.
139. Dror, O.; Schneidman-Duhovny, D.; Inbar, Y.; Nussinov, R.; Wolfson, H.J. Novel approach for efficient pharmacophore-basedvirtual screening: method and applications. J. Chem. Inf. Model.,2009, 49, 2333-2343.
140. Ma, D.-L.; Ma, V.P.-Y.; Chan, D.S.-H.; Leung, K.-H.; Zhong, H.-J.; Leung, C.-H. In silico screening of quadruplex-binding ligands.Methods., 2012, 57, 106-14.
141. Yang, S.Y. Pharmacophore modeling and applications in drugdiscovery: challenges and recent advances. Drug Discov. Today,2010, 15, 444-450.
142. Youngman, M.A.; McNally, J.J.; Lovenberg, T.W.; Reitz, A.B.; Willard, N.M.; Nepomuceno, D.H.; Wilson, S.J.; Crooke, J.J.; Rosenthal, D.; Vaidya, A.H.; Dax, S.L. alpha-Substituted N-(sulfonamido)alkyl-beta-aminotetralins: potent and selectiveneuropeptide Y Y5 receptor antagonists. J. Med. Chem., 2000, 43,346-350.
143. Gilligan, P.J.; Robertson, D.W.; Zaczek, R. Corticotropin releasingfactor (CRF) receptor modulators: progress and opportunities fornew therapeutic agents. J. Med. Chem., 2000, 43, 1641-1660.
144. Chen, Z.; Li, H.L.; Zhang, Q.J.; Bao, X.G.; Yu, K.Q.; Luo, X.M.; Zhu, W.L.; Jiang, H.L. Pharmacophore-based virtual screeningversus docking-based virtual screening: a benchmark comparisonagainst eight targets. Acta Pharmacol. Sin., 2009, 30, 1694-1708.
145. Hirayama, N. [Docking method for drug discovery]. YakugakuZasshi, 2007, 127, 113-122.
146. Minovski, N.; Perdih, A.; Solmajer, T. Combinatorially-generatedlibrary of 6-fluoroquinolone analogs as potential novelantitubercular agents: a chemometric and molecular modelingassessment. J. Mol. Model., 2012, 18, 1735-1753.
147. Yang, J.M.; Chen, Y.F.; Shen, T.W.; Kristal, B.S.; Hsu, D.F. Consensus scoring criteria for improving enrichment in virtualscreening. J. Chem. Inf. Model., 2005, 45, 1134-1146.
148. Kinnings, S.L.; Jackson, R.M. LigMatch: a multiple structure-based ligand matching method for 3D virtual screening. J. Chem.Inf. Model., 2009, 49, 2056-2066.
149. Ma, D.L.; Lai, T.S.; Chan, F.Y.; Chung, W.H.; Abagyan, R.; Leung, Y.C.; Wong, K.Y. Discovery of a drug-like G-quadruplexbinding ligand by high-throughput docking. ChemMedChem, 2008,3, 881-884.
150. Cuenca, F.; Moore, M.J.; Johnson, K.; Guyen, B.; De Cian, A.; Neidle, S. Design, synthesis and evaluation of 4,5-di-substitutedacridone ligands with high G-quadruplex affinity and selectivity,together with low toxicity to normal cells. Bioorg. Med.Chem.Bioorg. Med. Chem. Lett., 2009, 19, 5109-5113.
151. Lombardo, C.M.; Martinez, I.S.; Haider, S.; Gabelica, V.; DePauw, E.; Moses, J.E.; Neidle, S. Structure-based design ofselective high-affinity telomeric quadruplex-binding ligands.Chem. Commun. (Camb), 2010, 46, 9116-9118.
152. Guan, A.J.; Zhang, E.X.; Xiang, J.F.; Li, Q.; Yang, Q.F.; Li, L.; Tang, Y.L.; Wang, M.X. Effects of Loops and Nucleotides in G-Quadruplexes on Their Interaction with an Azacalixarene,Methylazacalix [6]pyridine. J. Phys. Chem. B, 2011, 43, 12584-90.
153. Dhamodharan, V.; Harikrishna, S.; Jagadeeswaran, C.; Halder, K.; Pradeepkumar, P.I. Selective G-quadruplex DNA stabilizing agentsbased on bisquinolinium and bispyridinium derivatives of 1,8-naphthyridine. J. Org. Chem., 2012, 77, 229-242.
154. Cosconati, S.; Marinelli, L.; Trotta, R.; Virno, A.; Mayol, L.; Novellino, E.; Olson, A.J.; Randazzo, A. Tandem application ofvirtual screening and NMR experiments in the discovery of brandnew DNA quadruplex groove binders. J. Am. Chem. Soc., 2009,131, 16336-16337.
155. Cosconati, S.; Rizzo, A.; Trotta, R.; Pagano, B.; Iachettini, S.; DeTito, S.; Lauri, I.; Fotticchia, I.; Giustiniano, M.; Marinelli, L.; Giancola, C.; Novellino, E.; Biroccio, A.; Randazzo, A. Shootingfor Selective Druglike G-Quadruplex Binders: Evidence forTelomeric DNA Damage and Tumor Cell Death. J. Med. Chem.,2012, 55, 9785-9792.
156. Kim, M.Y.; Duan, W.; Gleason-Guzman, M.; Hurley, L.H. Design, synthesis, and biological evaluation of a series offluoroquinoanthroxazines with contrasting dual mechanisms ofaction against topoisomerase II and G-quadruplexes. J. Med.Chem., 2003, 46, 571-583.
157. Lee, H.M.; Chan, D.S.; Yang, F.; Lam, H.Y.; Yan, S.C.; Che, C.M.; Ma, D.L.; Leung, C.H. Identification of natural productfonsecin B as a stabilizing ligand of c-myc G-quadruplex DNA byhigh-throughput virtual screening. Chem. Commun. (Camb), 2010,46, 4680-4682.
158. Naasani, I.; Seimiya, H.; Yamori, T.; Tsuruo, T. FJ5002: a potenttelomerase inhibitor identified by exploiting the disease-orientedscreening program with COMPARE analysis. Cancer Res., 1999,59, 4004-4011.
159. Franceschin, M.; Rossetti, L.; D'Ambrosio, A.; Schirripa, S.; Bianco, A.; Ortaggi, G.; Savino, M.; Schultes, C.; Neidle, S. Natural and synthetic G-quadruplex interactive berberinederivatives. Bioorg. Med. Chem. Lett., 2006, 16, 1707-1711.
160. Zhang, W.J.; Ou, T.M.; Lu, Y.J.; Huang, Y.Y.; Wu, W.B.; Huang, Z.S.; Zhou, J.L.; Wong, K.Y.; Gu, L.Q. 9-Substituted berberinederivatives as G-quadruplex stabilizing ligands in telomeric DNA.Bioorg. Med. Chem., 2007, 15, 5493-5501.
161. Ma, Y.; Ou, T.M.; Hou, J.Q.; Lu, Y.J.; Tan, J.H.; Gu, L.Q.; Huang, Z.S. 9-N-Substituted berberine derivatives: stabilization of G-quadruplex DNA and down-regulation of oncogene c-myc. Bioorg.Med. Chem., 2008, 16, 7582-7591.
162. Ma, Y.; Ou, T.M.; Tan, J.H.; Hou, J.Q.; Huang, S.L.; Gu, L.Q.; Huang, Z.S. Synthesis and evaluation of 9-O-substituted berberinederivatives containing aza-aromatic terminal group as highlyselective telomeric G-quadruplex stabilizing ligands. Bioorg. Med.Chem. Lett., 2009, 19, 3414-3417.
163. Parkinson, G.N.; Lee, M.P.; Neidle, S. Crystal structure of parallelquadruplexes from human telomeric DNA. Nature, 2002, 417, 876-880.
164. Totrov, M.; Abagyan, R. Flexible protein-ligand docking by globalenergy optimization in internal coordinates. Proteins, 1997, Suppl1, 215-220.
165. Irwin, J.J.; Shoichet, B.K. ZINC--a free database of commerciallyavailable compounds for virtual screening. J. Chem. Inf. Model.,2005, 45, 177-182.
166. Dai, J.; Punchihewa, C.; Ambrus, A.; Chen, D.; Jones, R.A.; Yang, D. Structure of the intramolecular human telomeric G-quadruplexin potassium solution: a novel adenine triple formation. NucleicAcids Res., 2007, 35, 2440-2450.
167. Holt, P.A.; Chaires, J.B.; Trent, J.O. Molecular docking ofintercalators and groove-binders to nucleic acids using Autodockand Surflex. J. Chem. Inf. Model., 2008, 48, 1602-1615.
168. Carley, D.W. Drug repurposing: identify, develop andcommercialize new uses for existing or abandoned drugs. Part II.IDrugs, 2005, 8, 310-313.
169. Chong, C.R.; Sullivan, D.J., Jr. New uses for old drugs. Nature,2007, 448, 645-646.
170. Schneider, P.; Tanrikulu, Y.; Schneider, G. Self-organizing maps indrug discovery: compound library design, scaffold-hopping,repurposing. Curr. Med. Chem., 2009, 16, 258-266.
171. Chan, D.S.; Yang, H.; Kwan, M.H.; Cheng, Z.; Lee, P.; Bai, L.P.; Jiang, Z.H.; Wong, C.Y.; Fong, W.F.; Leung, C.H.; Ma, D.L. Structure-based optimization of FDA-approved drug methyleneblue as a c-myc G-quadruplex DNA stabilizer. Biochimie, 2011,93, 1055-1064.
172. Ma, D.L.; Chan, D.S.; Fu, W.C.; He, H.Z.; Yang, H.; Yan, S.C.; Leung, C.H. Discovery of a natural product-like c-myc G-quadruplex DNA groove-binder by molecular docking. PLoS One,2012, 7, e43278.
173. Caceres, C.; Wright, G.; Gouyette, C.; Parkinson, G.; Subirana, J.A. A thymine tetrad in d(TGGGGT) quadruplexes stabilized withTl+/Na+ ions. Nucleic Acids Res., 2004, 32, 1097-1102.
174. Huey, R.; Morris, G.M.; Olson, A.J.; Goodsell, D.S. Asemiempirical free energy force field with charge-baseddesolvation. J. Comput. Chem., 2007, 28, 1145-1152.
175. Trott, O.; Olson, A.J. AutoDock Vina: improving the speed andaccuracy of docking with a new scoring function, efficientoptimization, and multithreading. J. Comput. Chem., 2010, 31, 455-461.
176. Perry, P.J.; Gowan, S.M.; Reszka, A.P.; Polucci, P.; Jenkins, T.C.; Kelland, L.R.; Neidle, S. 1,4- and 2,6-disubstitutedamidoanthracene-9,10-dione derivatives as inhibitors of humantelomerase. J. Med. Chem., 1998, 41, 3253-3260.
177. Neidle, S.; Harrison, R.J.; Reszka, A.P.; Read, M.A. Structure-activity relationships among guanine-quadruplex telomeraseinhibitors. Pharmacol. Ther., 2000, 85, 133-139.
178. Perry, P.J.; Reszka, A.P.; Wood, A.A.; Read, M.A.; Gowan, S.M.; Dosanjh, H.S.; Trent, J.O.; Jenkins, T.C.; Kelland, L.R.; Neidle, S. Human telomerase inhibition by regioisomeric disubstitutedamidoanthracene-9,10-diones. J. Med. Chem., 1998, 41, 4873-4884.
179. Read, M.A.; Wood, A.A.; Harrison, J.R.; Gowan, S.M.; Kelland, L.R.; Dosanjh, H.S.; Neidle, S. Molecular modeling studies on G-quadruplex complexes of telomerase inhibitors: structure-activityrelationships. J. Med. Chem., 1999, 42, 4538-4546.
180. Izbicka, E.; Wheelhouse, R.T.; Raymond, E.; Davidson, K.K.; Lawrence, R.A.; Sun, D.; Windle, B.E.; Hurley, L.H.; Von Hoff,D.D. Effects of cationic porphyrins as G-quadruplex interactiveagents in human tumor cells. Cancer Res., 1999, 59, 639-644.
181. Neidle, S. Human telomeric G-quadruplex: the current status oftelomeric G-quadruplexes as therapeutic targets in human cancer. FEBS J., 2010, 277, 1118-1125.
182. Balasubramanian, S.; Neidle, S. G-quadruplex nucleic acids astherapeutic targets. Curr. Opin. Chem. Biol., 2009, 13, 345-353.
183. Shi, D.F.; Wheelhouse, R.T.; Sun, D.; Hurley, L.H. Quadruplex-interactive agents as telomerase inhibitors: synthesis of porphyrinsand structure-activity relationship for the inhibition of telomerase.J. Med. Chem., 2001, 44, 4509-4523.
184. Neidle, S. Design Principles for Quadruplex-binding SmallMolecules. In Therapeutic Applications of Quadruplex NucleicAcids, Academic Press: Boston, 2012; pp 151-174.
185. Sun, D.; Thompson, B.; Cathers, B.E.; Salazar, M.; Kerwin, S.M.; Trent, J.O.; Jenkins, T.C.; Neidle, S.; Hurley, L.H. Inhibition ofhuman telomerase by a G-quadruplex-interactive compound. J.Med. Chem., 1997, 40, 2113-2116.
186. Harrison, R.J.; Gowan, S.M.; Kelland, L.R.; Neidle, S. Humantelomerase inhibition by substituted acridine derivatives. Bioorg.Med. Chem. Lett., 1999, 9, 2463-2468.
187. Han, H.; Langley, D.R.; Rangan, A.; Hurley, L.H. Selectiveinteractions of cationic porphyrins with G-quadruplex structures. J.Am. Chem. Soc., 2001, 123, 8902-8913.
188. Han, H.; Cliff, C.L.; Hurley, L.H. Accelerated assembly of G-quadruplex structures by a small molecule. Biochemistry, 1999, 38,6981-6986.
189. Fedoroff, O.Y.; Salazar, M.; Han, H.; Chemeris, V.V.; Kerwin, S.M.; Hurley, L.H. NMR-Based model of a telomerase-inhibitingcompound bound to G-quadruplex DNA. Biochemistry, 1998, 37,12367-12374.
190. Perry, P.J.; Read, M.A.; Davies, R.T.; Gowan, S.M.; Reszka, A.P.; Wood, A.A.; Kelland, L.R.; Neidle, S. 2,7-Disubstitutedamidofluorenone derivatives as inhibitors of human telomerase. J.Med. Chem., 1999, 42, 2679-2684.
191. Harrison, R.J.; Cuesta, J.; Chessari, G.; Read, M.A.; Basra, S.K.; Reszka, A.P.; Morrell, J.; Gowan, S.M.; Incles, C.M.; Tanious, F.A.; Wilson, W.D.; Kelland, L.R.; Neidle, S. Trisubstitutedacridine derivatives as potent and selective telomerase inhibitors. J.Med. Chem., 2003, 46, 4463-4476.
192. Koeppel, F.; Riou, J.F.; Laoui, A.; Mailliet, P.; Arimondo, P.B.; Labit, D.; Petitgenet, O.; Helene, C.; Mergny, J.L. Ethidiumderivatives bind to G-quartets, inhibit telomerase and act asfluorescent probes for quadruplexes. Nucleic Acids Res., 2001, 29,1087-1096.
193. Rosu, F.; De Pauw, E.; Guittat, L.; Alberti, P.; Lacroix, L.; Mailliet, P.; Riou, J.F.; Mergny, J.L. Selective interaction of ethidiumderivatives with quadruplexes: an equilibrium dialysis andelectrospray ionization mass spectrometry analysis. Biochemistry,2003, 42, 10361-10371.
194. Caprio, V.; Guyen, B.; Opoku-Boahen, Y.; Mann, J.; Gowan, S.M.; Kelland, L.M.; Read, M.A.; Neidle, S. A novel inhibitor of humantelomerase derived from 10H-indolo [3,2-b]quinoline. Bioorg. Med.Chem. Lett., 2000, 10, 2063-2066.
195. Mergny, J.L.; Lacroix, L.; Teulade-Fichou, M.P.; Hounsou, C.; Guittat, L.; Hoarau, M.; Arimondo, P.B.; Vigneron, J.P.; Lehn, J.M.; Riou, J.F.; Garestier, T.; Helene, C. Telomerase inhibitorsbased on quadruplex ligands selected by a fluorescence assay. Proc. Natl. Acad. Sci. USA, 2001, 98, 3062-3067.
196. Teulade-Fichou, M.P.; Carrasco, C.; Guittat, L.; Bailly, C.; Alberti, P.; Mergny, J.L.; David, A.; Lehn, J.M.; Wilson, W.D. Selectiverecognition of G-qQuadruplex telomeric DNA by abis(quinacridine) macrocycle. J. Am. Chem. Soc., 2003, 125, 4732-4740.
197. Gowan, S.M.; Harrison, J.R.; Patterson, L.; Valenti, M.; Read, M.A.; Neidle, S.; Kelland, L.R. A G-quadruplex-interactive potentsmall-molecule inhibitor of telomerase exhibiting in vitro and invivo antitumor activity. Mol. Pharmacol., 2002, 61, 1154-1162.
198. Shin-ya, K.; Wierzba, K.; Matsuo, K.; Ohtani, T.; Yamada, Y.; Furihata, K.; Hayakawa, Y.; Seto, H. Telomestatin, a noveltelomerase inhibitor from Streptomyces anulatus. J. Am. Chem.Soc., 2001, 123, 1262-1263.
199. Kim, M.Y.; Vankayalapati, H.; Shin-Ya, K.; Wierzba, K.; Hurley, L.H. Telomestatin, a potent telomerase inhibitor that interacts quitespecifically with the human telomeric intramolecular g-quadruplex.J. Am. Chem. Soc., 2002, 124, 2098-2099.
200. Mailliet, P.; Riou, J.F.; Mergny, J.L.; Laoui, A.; Lavelle, F.; Petitgenet, O. Chemical derivatives and their appliction asantitelomerase agent. US 6642964 B1, 2003.
201. Riou, J.F. G-quadruplex interacting agents targeting the telomericG-overhang are more than simple telomerase inhibitors. Curr. Med.Chem. Anticancer Agents, 2004, 4, 439-443.
202. Cuenca, F.; Greciano, O.; Gunaratnam, M.; Haider, S.; Munnur, D.; Nanjunda, R.; Wilson, W.D.; Neidle, S. Tri- and tetra-substitutednaphthalene diimides as potent G-quadruplex ligands. Bioorg. Med.Chem. Lett., 2008, 18, 1668-1673.
203. Nanjunda, R.; Musetti, C.; Kumar, A.; Ismail, M.A.; Farahat, A.A.; Wang, S.; Sissi, C.; Palumbo, M.; Boykin, D.W.; Wilson, W.D. Heterocyclic dications as a new class of telomeric G-quadruplextargeting agents. Curr. Pharm. Des., 2012, 18, 1934-1947.
204. Cabrera-Pérez, M.A.; Castillo-González, D.; Pérez-González, M.; Durán-Martínez, A. Telomerase Inhibitory Activity of AcridinicDerivatives: A 3D-QSAR Approach. QSAR Comb. Sci., 2009, 28,526-536.
205. Incles, C.M.; Schultes, C.M.; Kempski, H.; Koehler, H.; Kelland, L.R.; Neidle, S. A G-quadruplex telomere targeting agent producesp16-associated senescence and chromosomal fusions in humanprostate cancer cells. Mol. Cancer Ther., 2004, 3, 1201-1206.
206. Harrison, R.J.; Reszka, A.P.; Haider, S.M.; Romagnoli, B.; Morrell, J.; Read, M.A.; Gowan, S.M.; Incles, C.M.; Kelland, L.R.; Neidle, S. Evaluation of by disubstituted acridone derivatives as telomeraseinhibitors: the importance of G-quadruplex binding. Bioorg. Med.Chem. Lett., 2004, 14, 5845-5849.
207. Moore, M.J.; Schultes, C.M.; Cuesta, J.; Cuenca, F.; Gunaratnam, M.; Tanious, F.A.; Wilson, W.D.; Neidle, S. Trisubstitutedacridines as G-quadruplex telomere targeting agents. Effects ofextensions of the 3,6- and 9-side chains on quadruplex binding,telomerase activity, and cell proliferation. J. Med. Chem., 2006, 49,582-599.
208. Hutchinson, I.; McCarroll, A.J.; Heald, R.A.; Stevens, M.F. Synthesis and properties of bioactive 2- and 3-amino-8-methyl-8H-quino [4,3,2-kl]acridine and 8,13-dimethyl-8H-quino [4,3,2-kl]acridinium salts. Org. Biomol. Chem., 2004, 2, 220-228.
209. Schultes, C.M.; Guyen, B.; Cuesta, J.; Neidle, S. Synthesis,biophysical and biological evaluation of 3,6-bis-amidoacridineswith extended 9-anilino substituents as potent G-quadruplex-binding telomerase inhibitors. Bioorg. Med. Chem. Lett., 2004, 14,4347-4351.
210. Cookson, J.C.; Heald, R.A.; Stevens, M.F. Antitumor polycyclicacridines. 17. Synthesis and pharmaceutical profiles of pentacyclicacridinium salts designed to destabilize telomeric integrity. J. Med.Chem., 2005, 48, 7198-7207.
211. Heald, R.A.; Modi, C.; Cookson, J.C.; Hutchinson, I.; Laughton, C.A.; Gowan, S.M.; Kelland, L.R.; Stevens, M.F. Antitumorpolycyclic acridines. 8.(1) Synthesis and telomerase-inhibitoryactivity of methylated pentacyclic acridinium salts. J. Med. Chem., 2002, 45, 590-597.
212. Todeschini, R.; Ballabio, D.; Consonni, V.; Mauri, A.; Pavan, M. Mobydigs Computer Software, 1.0; TALETE srl: Milano, 2004.
213. Castillo-Gonzalez, D.; Cabrera-Perez, M.A.; Perez-Gonzalez, M.; Morales Helguera, A.; Duran-Martinez, A. Prediction of telomeraseinhibitory activity for acridinic derivatives based on chemicalstructure. Eur. J. Med. Chem., 2009, 44, 4826-4840.
214. Martins, C.; Gunaratnam, M.; Stuart, J.; Makwana, V.; Greciano, O.; Reszka, A.P.; Kelland, L.R.; Neidle, S. Structure-based designof benzylamino-acridine compounds as G-quadruplex DNAtelomere targeting agents. Bioorg. Med. Chem. Lett., 2007, 17,2293-2298.
215. Todeschini, R.; Consonni, V.; Pavan, M. Dragon for windows(Software for molecular descriptors calculation), Version 5.4;www.talete.mi.it: 2006.
216. Neidle, S.; Read, M.A. G-quadruplexes as therapeutic targets. Biopolymers, 2000, 56, 195-208.
217. Zambre, V.P.; Murumkar, P.R.; Giridhar, R.; Yadav, M.R. Structural investigations of acridine derivatives by CoMFA andCoMSIA reveal novel insight into their structures toward DNA G-quadruplex mediated telomerase inhibition and offer a highlypredictive 3D-model for substituted acridines. J. Chem. Inf. Model., 2009, 49, 1298-1311.
218. Cramer, R.D.; Patterson, D.E.; Bunce, J.D. Comparative molecularfield analysis (CoMFA). 1. Effect of shape on binding of steroids tocarrier proteins. J. Am. Chem. Soc., 1988, 110, 5959-5967.
219. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indicesin a comparative analysis (CoMSIA) of drug molecules to correlateand predict their biological activity. J. Med. Chem., 1994, 37, 4130-4146.
220. Huang, H.S.; Chou, C.L.; Guo, C.L.; Yuan, C.L.; Lu, Y.C.; Shieh, F.Y.; Lin, J.J. Human telomerase inhibition and cytotoxicity ofregioisomeric disubstituted amidoanthraquinones andaminoanthraquinones. Bioorg. Med. Chem., 2005, 13, 1435-1444.
221. Huang, H.S.; Chen, I.B.; Huang, K.F.; Lu, W.C.; Shieh, F.Y.; Huang, Y.Y.; Huang, F.C.; Lin, J.J. Synthesis and humantelomerase inhibition of a series of regioisomeric disubstitutedamidoanthraquinones. Chem. Pharm. Bull. (Tokyo), 2007, 55, 284-292.
222. Zagotto, G.; Sissi, C.; Lucatello, L.; Pivetta, C.; Cadamuro, S.A.; Fox, K.R.; Neidle, S.; Palumbo, M. Aminoacyl-anthraquinoneconjugates as telomerase inhibitors: synthesis, biophysical andbiological evaluation. J. Med. Chem., 2008, 51, 5566-5574.
223. Belmont, P.; Bosson, J.; Godet, T.; Tiano, M. Acridine andacridone derivatives, anticancer properties and synthetic methods:where are we now? Anticancer Agents Med. Chem., 2007, 7, 139-169.
224. Zambre, V.P.; Murumkar, P.R.; Giridhar, R.; Yadav, M.R. Development of highly predictive 3D-QSAR CoMSIA models foranthraquinone and acridone derivatives as telomerase inhibitorstargeting G-quadruplex DNA telomere. J. Mol. Graph. Model.,2010, 29, 229-239.
225. Chen, S.B.; Tan, J.H.; Ou, T.M.; Huang, S.L.; An, L.K.; Luo, H.B.; Li, D.; Gu, L.Q.; Huang, Z.S. Pharmacophore-based discovery oftriaryl-substituted imidazole as new telomeric G-quadruplex ligand.Bioorg. Med. Chem. Lett., 2011, 21, 1004-1009.
226. Hawkins, P.C.; Skillman, A.G.; Nicholls, A. Comparison of shape-matching and docking as virtual screening tools. J. Med. Chem.,2007, 50, 74-82.
227. Gonzalez, D.C.; Machado, G.P.; Guedin, A.; Mergny, J.L.; Cabrera-Perez, M.A. FDA-approved drugs selected using virtualscreening bind specifically to G-quadruplex DNA. Curr. Pharm.Des., 2013.(In press)
228. Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A.C.; Wishart, D.S. DrugBank 3.0: a comprehensive resourcefor 'omics' research on drugs. Nucleic Acids Res., 2011, 39, 1035-1041.
229. Wishart, D.S.; Knox, C.; Guo, A.C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. DrugBank: a knowledgebasefor drugs, drug actions and drug targets. Nucleic Acids Res., 2008,36, 901-906.
230. Wishart, D.S.; Knox, C.; Guo, A.C.; Shrivastava, S.; Hassanali, M.; Stothard, P.; Chang, Z.; Woolsey, J. DrugBank: a comprehensiveresource for in silico drug discovery and exploration. Nucleic AcidsRes., 2006, 34, 668-672.